Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Range Finding Study of the Efficacy, Safety, and Pharmacokinetics of CRB-913 in Participants With Obesity With a Single Cohort Open-label Exploratory Pharmacokinetic Lead-In

NCT07310901 is registered in ClinicalTrials.gov with Corbus Pharmaceuticals Inc. as lead sponsor.

NCT NCT07310901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07310901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Range Finding Study of the Efficacy, Safety, and Pharmacokinetics of CRB-913 in Participants With Obesity With a Single Cohort Open-label Exploratory Pharmacokinetic Lead-In
Lead sponsor
Corbus Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 4, 2025
Completion date
August 3, 2026
Enrollment
254 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

obese but otherwise healthy participants